NewcelX AG, formerly NLS Pharmaceutics AG, is a Switzerland-based company primarily engaged in the biotechnology industry. The Company focuses on the discovery and development of therapies for rare and complex central nervous system (CNS) disorders, including sleep and neurodevelopmental conditions. The Company offers products like Quilience, which is a clinical-stage pharmaceutical compound. It aims to support the treatment of narcolepsy by modulating monoamine neurotransmission and orexin receptor activity. The Company also develops product like Nolazol, a treatment candidate for Attention Deficit Hyperactivity Disorder (ADHD). The Company is a publicly traded company, listing on the NASDAQ.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	58.79M 51.54M 47.51M 44.48M 83.41M 5.55B 85.14M 571M 221M 2.74B 221M 216M 9.5B	P/E 2024 *	-	P/E 2025	-2.81x
Enterprise Value	56.94M 49.92M 46.02M 43.08M 80.79M 5.37B 82.47M 553M 214M 2.65B 214M 209M 9.21B	EV / Sales 2024 *	-	EV / Sales 2025	-
Free-Float	35.62%	Yield 2024 *	-	Yield 2025	-

06-15	NewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential Of Its Stem Cell Technology Platform	CI
05-27	Newcelx submits pre-IND package to FDA for NCEL-101 for treatment of type 1 diabetes	RE
05-27	NewcelX Submits Pre-IND Package To FDA For NCEL-101 For The Treatment Of Type 1 Diabetes	CI
05-01	NewcelX Ltd. announced that it has received $1.349994 million in funding	CI
04-30	NewcelX Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-29	NewcelX Ltd. Auditor Raises 'Going Concern' Doubt	CI
04-20	Newcelx updates corporate presentation to highlight type 1 diabetes flagship program	RE
04-02	NewcelX Ltd. announced that it expects to receive $1.349994 million in funding	CI
03-09	NewcelX announces strategic collaboration with Eledon Pharmaceuticals to advance NCEL-101 program for type 1 diabetes	RE
01-12	Newcelx Ltd. Announces Positive Results from International Collaborative Study	CI
01-05	NewcelX Ltd. Announces Appointment Of Dr. Julien Boisdron To Scientific Advisory Board	CI
11-17	NewcelX Ltd. Announces Appointment of Prof. Jeremy Shefner to the Scientific Advisory Board	CI
11-07	NewcelX Ltd. Announces Chief Financial Officer Changes, Effective December 10, 2025	CI

05-27	NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes	GL
04-30	NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026	AQ
04-20	NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference	GL
04-01	NewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium Pricing	GL
03-09	NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes	PR

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
KADIMASTEM	-0.78%	+153.00%	-	-	19.6M
LONZA GROUP AG	+0.90%	+7.20%	-5.65%	+1.02%	46.2B
REVOLUTION MEDICINES, INC.	+2.19%	+11.71%	+393.31%	+580.42%	38.71B
IQVIA HOLDINGS INC.	+2.53%	+13.93%	+21.38%	-12.81%	31.9B
BEONE MEDICINES AG	+1.65%	+3.61%	+16.04%	+55.62%	31.12B
CELLTRION, INC.	-4.16%	-2.58%	+8.94%	+25.31%	23.77B
ASCENDIS PHARMA A/S	-0.32%	+12.96%	-	-	16.2B
MEDPACE HOLDINGS, INC.	+1.37%	+14.53%	+69.64%	+130.07%	15.05B
EUROFINS SCIENTIFIC SE	-0.09%	+8.57%	+14.03%	+21.98%	13.74B
IONIS PHARMACEUTICALS, INC.	+3.63%	+9.53%	+103.97%	+98.73%	13.42B
Average	+0.70%	+9.14%	+77.71%	+112.54%	25.57B
Weighted average by Cap.	+0.97%	+8.71%	+88.79%	+131.00%

	2024	2025
Net sales	-	-
Net income	-26.55M -23.28M -21.46M -20.09M -37.67M -2.5B -38.46M -258M -99.8M -1.24B -99.7M -97.53M -4.29B	-8.3M -7.28M -6.71M -6.28M -11.78M -783M -12.02M -80.63M -31.2M -387M -31.17M -30.49M -1.34B
Net Debt	7.35M 6.44M 5.94M 5.56M 10.42M 693M 10.64M 71.37M 27.62M 343M 27.59M 26.99M 1.19B	-1.85M -1.62M -1.49M -1.4M -2.62M -174M -2.67M -17.93M -6.94M -86.06M -6.93M -6.78M -298M

Kadimastem Stock OTC Markets

Stocks

KMSTF

IL0011284614

Biotechnology & Medical Research

Valuation: Kadimastem

Latest news : Kadimastem

Analysts' recommendations: Kadimastem

Press Releases: Kadimastem

Quotes and Performance

Other Biotechnology & Medical Research

Financials

Company Profile